Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2010

01-12-2010 | Healthcare Policy and Outcomes

Patterns of Referral and Resection Among Patients with Liver-Only Metastatic Colorectal Cancer (MCRC)

Authors: Doran Ksienski, MD, Ryan Woods, MSc, Caroline Speers, BA, Hagen Kennecke, MD

Published in: Annals of Surgical Oncology | Issue 12/2010

Login to get access

Abstract

Background

Rates of metastatectomy vary among patients with liver-only metastatic colorectal cancer (MCRC). This study describe predictors of referral to a hepatobiliary surgeon (HBS) and hepatic resection in a population-based setting.

Materials and Methods

Patients referred to the British Columbia Cancer Agency (BCCA) with synchronous or relapsed MCRC isolated to the liver in 2002–2004 were identified. Classification of tumor burden as “high” or “low” was based on prognostic features defined by LiverMetSurvery registry. Metastases larger than 5 cm, bilobar, or more than 3 metastases were classified as high tumor burden. Multivariate logistic regression models were used to identify predictors of HBS referral and subsequent metastatectomy. Overall survival was calculated by the Kaplan–Meier method.

Results

Of 618 patients with isolated hepatic metastasis, 148 (24%) were referred to a HBS and 99 (16%) underwent resection. Advanced age was the most common reason for not referring 64 patients (10%) with ECOG performance status 0/1 and low tumor burden. In multivariate analysis, variables associated with referral were younger age (P < .001), ECOG performance status 0/1 (P < .002), chemotherapy for metastatic disease (P = .007), 1–3 metastasis (P < .001), and unilobar disease (P < .001). Median patient survival was 0.99 years (95% confidence interval [95% CI], 0.89–1.10 years) among nonreferred, 1.83 years (95% CI, 1.37–2.31 years) if referred but not resected, and 3.85 years (95% CI, 2.90–4.80 years) if resected.

Conclusion

A significant proportion of patients are not referred to a HBS because of advanced chronological age. Resection of hepatic metastases was associated with improved overall survival irrespective of initial tumor burden.
Literature
1.
go back to reference Adam R, Aloia T, Figueras J, Capussotti L, Poston G, Mentha G, et al. LiverMetSurvey: analysis of clinicopathologic factors associated with the efficacy of preoperative chemotherapy in 2,122 patients with colorectal liver metastases. ASCO meeting abstracts. 2006;24:3521. Adam R, Aloia T, Figueras J, Capussotti L, Poston G, Mentha G, et al. LiverMetSurvey: analysis of clinicopathologic factors associated with the efficacy of preoperative chemotherapy in 2,122 patients with colorectal liver metastases. ASCO meeting abstracts. 2006;24:3521.
2.
go back to reference Wood CB, Gillis CR, Blumgart LH. A retrospective of the natural history of patients with liver metastases from colorectal cancer. Oncol J. 1976;2:285–8. Wood CB, Gillis CR, Blumgart LH. A retrospective of the natural history of patients with liver metastases from colorectal cancer. Oncol J. 1976;2:285–8.
3.
go back to reference Poston G, Adam R, Alberts S, Curley S, Figueras J, Haller D, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125–34.CrossRefPubMed Poston G, Adam R, Alberts S, Curley S, Figueras J, Haller D, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23:7125–34.CrossRefPubMed
4.
go back to reference Brenner B, Leonard G, Kemeny N. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases. J Clin Oncol. 2005;23:2038–48.CrossRefPubMed Brenner B, Leonard G, Kemeny N. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases. J Clin Oncol. 2005;23:2038–48.CrossRefPubMed
5.
go back to reference Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg. 2001;88:165–75.CrossRefPubMed Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg. 2001;88:165–75.CrossRefPubMed
6.
go back to reference Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg. 2000;232:777–85.CrossRefPubMed Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg. 2000;232:777–85.CrossRefPubMed
7.
go back to reference Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57.CrossRefPubMed Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57.CrossRefPubMed
8.
go back to reference Berber E, Pelley R, Siperstein A. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23:1358–64.CrossRefPubMed Berber E, Pelley R, Siperstein A. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol. 2005;23:1358–64.CrossRefPubMed
9.
go back to reference Page DL, Fleming ID, Fritz A, et al. AJCC cancer staging manual, 7th ed. Philadelphia: Lippincott Raven Publishers; 2010. pp. 143–59. Page DL, Fleming ID, Fritz A, et al. AJCC cancer staging manual, 7th ed. Philadelphia: Lippincott Raven Publishers; 2010. pp. 143–59.
10.
go back to reference Hamilton S, Aaltonen L. World health organization classification of tumours: pathology and genetics of tumours of the digestive system. 3rd ed. New York: WHO Publications; 2000. Hamilton S, Aaltonen L. World health organization classification of tumours: pathology and genetics of tumours of the digestive system. 3rd ed. New York: WHO Publications; 2000.
11.
go back to reference Hosmer, DW, Lemeshow, S. Applied logistic regression. 2nd ed. New York: Wiley, 2002:91–128. Hosmer, DW, Lemeshow, S. Applied logistic regression. 2nd ed. New York: Wiley, 2002:91–128.
12.
go back to reference O’Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008;26:2336–41.CrossRefPubMed O’Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, et al. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008;26:2336–41.CrossRefPubMed
13.
go back to reference Simons JP, Ng SC, Hill JS, Shah SA, Zhou Z, Tseng JF. In-hospital mortality for liver resection for metastases: a simple risk score. J Surg Res. 2009;156:21–5.CrossRefPubMed Simons JP, Ng SC, Hill JS, Shah SA, Zhou Z, Tseng JF. In-hospital mortality for liver resection for metastases: a simple risk score. J Surg Res. 2009;156:21–5.CrossRefPubMed
14.
go back to reference Robertson DJ, Stukel TA, Gottlieb J, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases. Cancer. 2009;115:752–9.CrossRefPubMed Robertson DJ, Stukel TA, Gottlieb J, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases. Cancer. 2009;115:752–9.CrossRefPubMed
15.
go back to reference Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35.CrossRefPubMed Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27:1829–35.CrossRefPubMed
16.
go back to reference Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal cancer metastases: expert consensus statement. Ann Surg Oncol. 2006;12:1271–80.CrossRef Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal cancer metastases: expert consensus statement. Ann Surg Oncol. 2006;12:1271–80.CrossRef
17.
go back to reference Fong Y, Blumgart L, Fortner J. Pancreatic or liver resection is safe and effective for elderly. Ann Surg. 1995;222:426–37.PubMed Fong Y, Blumgart L, Fortner J. Pancreatic or liver resection is safe and effective for elderly. Ann Surg. 1995;222:426–37.PubMed
18.
go back to reference Fong Y, Salo L. Surgical therapy of hepatic colorectal metastasis. Semin Oncol. 1999;26:514–23.PubMed Fong Y, Salo L. Surgical therapy of hepatic colorectal metastasis. Semin Oncol. 1999;26:514–23.PubMed
19.
go back to reference Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199:502–8.CrossRefPubMed Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199:502–8.CrossRefPubMed
20.
go back to reference Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumors. Br J Surg. 2002;89:1206–22.CrossRefPubMed Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumors. Br J Surg. 2002;89:1206–22.CrossRefPubMed
Metadata
Title
Patterns of Referral and Resection Among Patients with Liver-Only Metastatic Colorectal Cancer (MCRC)
Authors
Doran Ksienski, MD
Ryan Woods, MSc
Caroline Speers, BA
Hagen Kennecke, MD
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1304-9

Other articles of this Issue 12/2010

Annals of Surgical Oncology 12/2010 Go to the issue